REC-994
REC-994 is Recursion Pharmaceuticals' investigational small-molecule drug for cerebral cavernous malformation (CCM) — a rare neurological condition in which clusters of abnormally formed blood vessels in the brain or spinal cord bleed unpredictably, causing seizures, headaches, and focal neurological deficits. Identified by Recursion's AI phenomics platform, the compound is believed to modulate oxidative stress pathways that contribute to CCM lesion formation and vascular leakage. REC-994 is Recursion's most clinically advanced asset and represents the first Phase 2 efficacy test of a drug discovered through a purely computational, image-based AI approach.
Upcoming catalysts
Programs
Recurrent Glioblastoma
Recurrent glioblastoma is uniformly fatal — median OS after recurrence is ~6 months — with no therapy demonstrating an OS benefit in a randomized trial since bevacizumab showed only PFS improvement; there is no standard of care. This Phase 2 trial is the first prospective efficacy test of a Recursion AI-discovered drug, measuring OS versus historical controls and 6-month PFS rate in post-temozolomide rGBM patients.